Startups
Prodromic
Cambridge, United Kingdom
Prodromic develops multimodal AI software to forecast brain-disease trajectories, initially dementia, using clinical information such as cognitive tests, imaging, biomarkers and genetics. Its software produces interpretable patient-level predictions for research, trial stratification and treatment-development workflows. It is a University of Cambridge spinout founded by neuroscientists Zoe Kourtzi and Andrew Welchman. The exact legal issuer is active UK Prodromic Ltd, company15868742, incorporated31July2024; its two registered directors match the founders published on its own website. The own solutions page expressly states that these are research tools and are not to be used as medical devices. Retrospective dataset validation and trial reanalysis are research claims, not marketing approval or demonstrated prospective clinical benefit. Cambridge Enterprise Ventures explicitly identifies Prodromic as a portfolio company and the START2.0 accelerator lists it in2025. Public sources do not establish a priced round, individual investment amount, payment date or exact financing instrument. An HSBC Innovation Banking security charge registered18August2025 establishes a security relationship, not a disclosed facility size, actual loan draw or additional paid funding event. No debt cash is inferred from that filing.
Founded 2024
Team
 Andrew WelchmanCo-founder and Chief Executive Officer · Director |
 Zoe KourtziCo-founder and Chief Scientific Officer · Director |